Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2021-12-09
Target enrollment:
Participant gender:
Summary
NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive
NHL who are candidate for high-dose therapy should receive combination of cytotoxic
chemotherapies as 2nd line treatment. However, proportion of patients who are adequately
salvaged by second line chemotherapy and high-dose chemotherapy with stem cell rescue is
unsatisfactory. Moreover, many fragile patients are unfit for salvage cytotoxic chemotherapy
and/or high-dose chemotherapy. Hence, most of patients with relapsed/refractory aggressive
B-cell NHL is ultimately candidate for less-cytotoxic drugs with targeted approach. This
trial is phase II trial of acalabrutinib in combination with rituximab and lenalidomide for
these patients.